DeepSeq.AI, a leading startup in AI-driven protein drug discovery, is excited to announce its selection as a winner of 2024 Golden Ticket Competition sponsored by Ono Pharmaceutical Co.,Ltd. (ONO). This esteemed award, part of a prestigious collaboration between ONO and MBC BioLabs, demonstrates DeepSeq.AI's pioneering role in advancing life sciences research.
The Golden Ticket provides DeepSeq.AI with one year of complimentary lab space and access to cutting-edge facilities at MBC BioLabs in San Francisco. MBC BioLabs is renowned not only for its state-of-the-art equipment and lab facilities but also for its vibrant community of top-tier startups. Notable companies such as Alector, Cell Design Labs, Mammoth Biosciences, and BigHatBiosciences have all emerged from the MBC BioLabs ecosystem.
Sponsored by ONO, theGolden Ticket Competition supports early-stage companies in oncology, immunology, neurology, and specialty areas. DeepSeq.AI was selected for its ground breaking work in using AI to design and optimize protein drugs, setting itself apart in a competitive field of applicants.
“Winning the Golden Ticket is a tremendous honor for DeepSeq.AI,” said Andrew Chang, Ph.D., CEO of DeepSeq.AI. “This recognition not only validates our innovative approach but also provides us with critical resources and support to accelerate our research and development efforts. We are eager to be part of the MBC BioLabs community to push the boundaries of drug discovery.”
DeepSeq.AI looks forward to utilizing the GoldenTicket to further its mission of transforming the landscape of drug discovery through innovative AI solutions and screening technologies.
About Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co.,Ltd., headquartered in Osaka, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. ONO focuses its research on the oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative medicines. For further information, please visit the company’s website at https://www.ono-pharma.com.
About MBC BioLabs
MBC BioLabs is a premier life science incubator that provides early-stage biotech companies with the resources and support necessary to thrive. Through its network of state-of-the-art laboratories, industry partnerships, and engaged bioentrepreneur community, MBC BioLabs empowers startups to accelerate their research and propel groundbreaking ideas into transformative therapies. Since opening in 2013, MBC BioLabs has helped launch and grow over 300 companies. These companies have brought 153 programs to the clinic, produced 17 approved diagnostics, and raised over $14 billion. More information is available at www.mbcbiolabs.com
